PDCD1 and urinary bladder cancer: In many preclinical models, including melanoma, breast, and bladder cancers, CCR2 antagonism coupled with anti-PD-1 therapy enhanced the anti-tumor response of mice compared to anti-PD-1 monotherapy [168].